To crack the code of FSHD, patients are absolutely essential
All of the breakthroughs—the discovery of the genetic causes, understanding why some patients vary so greatly in the severity of their symptoms, teasing out the biochemical pathways that could point to future treatments—were made because patients stepped up to the plate.
Too often, we hear patients say they’ll volunteer when there’s a treatment. But we will never get to a treatment unless patients participate in fundamental research now. FSHD is uniquely human, so no laboratory mouse can ever fully model the disease. The genetic “package” that causes FSHD is found only in people. We owe an enormous debt to the patients who give DNA samples. Who submit to long interviews and exhausting physical tests. Allow a surgeon to cut out a small muscle sample. Who fight claustrophobia to lie in the narrow bore of an MRI machine.
Equally important are patients’ family members, both affected and unaffected, who provide the best experimental controls because of their shared genetic and environmental backgrounds. A parent or sibling who has very mild symptoms may hold the key to understanding the factors that protect against the full-blown development of FSHD symptoms in a more severely affected family member.
We are more hopeful today than ever before that a treatment is within sight. We cannot guarantee when that treatment will arrive, but here’s one thing we guarantee: If you volunteer for research, your participation will without question help move us a step closer to that day.
Scientific Overview of FSHD
Read the latest on wikipedia
Glossary of Scientific Terms
FSHD Society signs agreement to expand CTRN
From PRWeb The FSHD Society announced today that it has signed a memorandum of understanding to enter into a three-year agreement to enable the expansion of the international facioscapulohumeral muscular dystrophy… Read More »
Charis Himeda talks about CRISPR and FSHD
From the FSHD Society’s webinar series on facioscapulohumeral muscular dystrophy. Charis Himeda, PhD, of the University of Nevada Reno, discusses her groundbreaking work showing how CRISPR “gene editing” technology can… Read More »
Fulcrum Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
August 19, 2019 at 7:00 AM EDT From Fulcrum press release. PDF Version CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving… Read More »
The disappearing bomb
How DUX4 could cause FSHD without actually being there BY AMANDA HILL, HIGHLANDS RANCH, COLORADO In the FSHD research field, there is an emerging idea that the damage caused by… Read More »